{"url_path":"/sec/apls/8-k/2026-05-14/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1492422/0001193125-26-222923-index.html","accession_number":"0001193125-26-222923","cik":"0001492422","ticker":"APLS","issuer_name":"Apellis Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1492422/0001193125-26-222923-index.html","primary_entity_key":"0001492422","primary_entity_name":"Apellis Pharmaceuticals, Inc."},"word_count":210,"has_tables":true,"body_markdown":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nEffective as of the Effective Time, Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof. These resignations were tendered as a result of the Merger and were not a result of any disagreement between the Company and the directors on any matter relating to the Company’s operations, policies or practices.\n\n \n\nIn accordance with the terms of the Merger Agreement, effective as of the Effective Time, the director of Purchaser as of immediately prior to the Effective Time, Michael Dambach, became the director of the Company.\n\nBiographical and other information with respect to Michael Dambach is set forth in Schedule I to the Offer to Purchase, a copy of which was filed as Exhibit (a)(1)(A) to the Tender Offer Statement on Schedule TO filed by Biogen on April 14, 2026 and is incorporated herein by reference.\n\nThe information set forth in the Introductory Note of this Current Report on Form 8-K is incorporated herein by reference."}